Vera Therapeutics, Inc. (VERA) company profile
Close on Nov 16, 2026Market cap $1.94BP/E –Yield –
About Vera Therapeutics
Pharmaceutical Preparations, SIC 2834
Vera Therapeutics, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing therapies for individuals with severe immunological conditions. The company's primary product candidate is atacicept, a fusion protein designed for at-home self-administration via subcutaneous injection to treat autoimmune kidney conditions, most notably immunoglobulin A nephropathy. In addition to atacicept, its development programs involve investigational candidates such as MAU868 and VT-109 under licensing agreements. The company operates in the biotechnology sector and aims its investigational therapies at patients suffering from serious autoimmune and kidney disorders.
The company maintains its principal executive offices in Brisbane, California. Its operations and clinical research activities are conducted within the United States, supported by external partners for clinical trials and contract manufacturing. The provided text mentions no retail locations, operational facilities outside the United States, or additional branch offices.
Summary of the business section of Vera Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vera Therapeutics, Inc.
- Headquarters
- Brisbane, CA
- Address
- 2000 Sierra Point Parkway, Suite 1200 94005
- Phone
- (650) 770-0077
- Website
- veratx.com
- Employees
- 249, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- VERA
- Exchange
- Nasdaq
- IPO date
- May 17, 2021
- Shares outstanding
- 72M, Jul 29, 2026
- Public float
- $1.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 23-for-2, May 7, 2021
- SEC CIK
- 1831828
- CUSIP
- 92337R101
- ISIN
- US92337R1014
- FIGI
- BBG00Q72WYG3
- Share class FIGI
- BBG00Q72WYH2
- EIN
- 81-2744449
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO, Director | 475,774 |
| Joseph R. Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 |
| Nancy Lee Boman | Chief Regulatory Officer | 44,987 |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 |
| Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 |
| David Lee Johnson | Chief Operating Officer | 45,727 |
| William D. Turner | Chief Regulatory Officer | 45,313 |
| Robert Brenner | Chief Medical Officer | 50,947 |
| Jason S. Carter | Chief Legal Officer | 49,136 |
| Scott W. Morrison | Director | – |
| Michael Morrissey | Director | 0 |
| Andrew Cheng | Director | 17,488 |
| James R. Meyers | Director | – |
| Kimball Hall | Director | 0 |
| Christy J. Oliger | Director | 2,987 |
| Beth C. Seidenberg | Director | 135,565 |
| Patrick G. Enright | Director | 3,602,475 |
| Christopher Hite | Director | – |
| Maha Katabi | Director | 5,975,429 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $6.99M | $9.13M | $2.63M | $262 | $137 |
| FY2024 | $5.65M | $31.24M | $5.05M | $219 | $103 |
| FY2023 | $3.43M | $1.99M | $1.39M | $79 | $105 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Marshall Fordyce, M.D. President and Chief Executive Officer | $660.00K | $2.36M | $3.42M | $554.40K | – | $6.99M | +24% |
| Sean Grant Chief Financial Officer | $507.00K | $784.94K | $1.14M | $283.92K | $3.00K | $2.72M | +21% |
| David Johnson Chief Operating Officer | $510.00K | $784.94K | $1.14M | $285.60K | $3.00K | $2.72M | – |
| Robert Brenner, M.D. Chief Medical Officer | $509.00K | $784.94K | $1.14M | $285.04K | $3.00K | $2.72M | -39% |
| William Turner Chief Regulatory Officer | $473.00K | $656.55K | $951.75K | $264.88K | – | $2.35M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 17, 2021
- Offer price
- $11.00
- Securities offered
- 4,350,000
- Gross proceeds
- $47.85M
- Exchange
- Nasdaq
- First trading day
- May 14, 2021
- First-day close
- $11.50+4.5%
- Lock-up ends (est.)
- Nov 10, 2021
“The initial public offering price is $11.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 249 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 17, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| May 11, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?